Multi-site GSI ESBL Report

3$7,(17,' BBBBBBBBBBBBBBBBBBBBBBBBBBB

'$7(5(3257('72(,36,7(

___ ___ - ___ ___ - ___ ___ ___ ___

1Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae
0XOWLVLWH*UDP1HJDWLYH6XUYHLOODQFH,QLWLDWLYH0X*6,

Form Approved
OMB No. 0920-0978

+HDOWKFDUH-$VVRFLDWHG,QIHFWLRQs&RPPXQLW\,QWHUIDFH+$,&&DVH5HSRUW
Patient’s Name:

Phone no. (

)
MRN:

Address:
City:

State

ZIP:

Hospital:

----Patient Identifier information is not transmitted to CDC---'(02*5$3+,&6
 67$7(

 &2817<

 67$7(,'

BBBBBBBB

BBBBBBBBBBBBB

BBBBBBBBBBBBBBBBBBBBB___ ___

___ ___ - ___ ___ - ___ ___ ___ ___

 $*(

D(7+1,&25,*,1

 6(;$7%,57+

 '$7(2)%,57+

____ ____ ____

□ Days □ Mos. □ Yrs.

D/$%25$725<,':+(5(
,1&,'(1763(&,0(1,'(17,),('
BBBBBBBBBBBBBBBBBBBBBBBB

□ MALE □ FEMALE
□ Unknown
□ Check if transgender

□
□
□

E)$&,/,7<,':+(5(3$7,(1775($7('
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB

E5$&(&KHFNDOOWKDW$SSO\

□ American Indian or Alaska □ Native Hawaiian or

Hispanic or Latino
Not Hispanic or Latino
Unknown

Native

Other Pacific Islander

□ White
□ Asian
□ Black or African American □ Unknown

10. 25*$1,60
Extended-Spectrum Cephalosporin-resistant:

 '$7(2),1&,'(1763(&,0(1&2//(&7,21',6&
___ ___ - ___ ___ - ___ ___ ___ ___

ƑEscherichia coli
ƑKlebsiella pneumoniae
ƑKlebsiella oxytoca

 ,1&,'(1763(&,0(1&2//(&7,216,7(

□ Blood □ Bone □ CSF □ Internal body site (specify):___________ □ Joint/synovial fluid □ Muscle
□ Peritoneal fluid □ Pericardial fluid □ Pleural fluid □ Urine □ Other normally sterile site (specify): ______________

 /2&$7,212)63(&,0(1&2//(&7,21

□ 2873$7,(17

□ ,13$7,(17

Facility
ID:____________
Emergency room

Facility
ID:____________

□
□ Clinic/Doctor's office
□ Dialysis center
□ Surgery
□ Observational/

□ ICU
□ OR
□ Radiology
□ Other inpatient

Clinical decision unit

□ /7&)

Facility
ID:____________

□ /7$&+

Facility
ID:____________

□ $XWRSV\
□ 2WKHUVSHFLI\
BBBBBBBBBBBBBBB

□ 8QNQRZQ

□ Other outpatient

 :$67+(3$7,(17+263,7$/,=('217+('$<2)25,17+(
&$/(1'$5'$<6$)7(57+(',6&"

□ Yes □ No □ Unknown
IF YES, DATE OF ADMISSION:

___ ___ - ___ ___ - ___ ___ ___ ___

□ Survived

16. 3$7,(17287&20(

DATE OF DISCHARGE: ___ ___ - ___ ___ - ___ ___ ___ ___ OR

□ Date unknown

IF SURVIVED, DISCHARGED TO:

□ Left against medical advice (AMA)

 :+(5(:$67+(3$7,(17/2&$7('217+(5'&$/(1'$5'$<%()25(7+(
',6&"

□ Private residence
□ LTCF

Facility ID: _______________

□

Hospital inpatient
Facility ID: _______________
Was the patient transferred from
this hospital?

□ LTACH

Facility ID: ___________________

□ Homeless
□ Incarcerated
□ Other (specify):________________
□ Unknown

□ Yes □ No □ Unknown
D:$67+(3$7,(17,1$1,&8,17+('$<6%()25(7+(',6&"

□ Yes □ No □ Unknown

IF YES, DATE OF ICU ADMISSION: ___ ___ - ___ ___ - ___ ___ ___ ___ OR

□ Date unknown

E:$67+(3$7,(17,1$1,&8217+('$<2),1&,'(1763(&,0(1&2//(&7,21
25,17+('$<6$)7(57+(',6&"

□ Yes □ No □ Unknown

IF YES, DATE OF ICU ADMISSION: ___ ___ - ___ ___ - ___ ___ ___ ___ OR

□ Died

DATE OF DEATH:

□ Private residence □ LTCF Facility ID:______ □ LTACH Facility ID: ______
□ Other (specify): ________ □ Unknown

___ ___ - ___ ___ - ___ ___ ___ ___ OR

□ Date unknown

□ Unknown
□ Date unknown

ON THE DAY OF OR IN THE 6 CALENDAR DAYS BEFORE DEATH, WAS THE PATHOGEN
OF INTEREST ISOLATED FROM A SITE THAT MEETS THE CASE DEFINITION?

□

Yes

□ No □ Unknown

Public reporting burden of this collection of information is estimated to average 28 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed,
and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS
D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

Version Date: 08/2020

PAGE 1 OF 4

Form Approved
OMB No. Form
0920-0978
Approved
OMB
No. 0920-0978
Exp. Date:
XX-XX-XXXX

□

a7<3(62),1)(&7,21$662&,$7(':,7+&8/785(6&KHFNDOOWKDWDSSO\
None
□ Epidural Abscess
□ Cellulitis
□
□ Abscess, not skin
□ Chronic ulcer/wound (not decubitus) □ Meningitis
□
□ AV fistula/graft infection
□ Osteomyelitis
□ Decubitus/pressure ulcer
□
□ Bacteremia
□ Peritonitis
□ Empyema
□
□ Bursitis
□ Pneumonia
□
□ Catheter site infection (CVC) □ Endocarditis

□ None □ Unknown

□ Unknown □ Colonized

Pyelonephritis
Septic arthritis
Septic emboli
Septic shock
Skin abscess

□
□
□
□
□

E5(&855(1787,

Surgical incision infection
Surgical site infection (internal)
Traumatic wound
Urinary tract infection
Other (specify): ____________

□ Yes
□ No
□ Unknown

881'(5/<,1*&21',7,216&KHFNDOOWKDWDSSO\

,00812&203520,6('&21',7,21

&+521,&/81*',6($6(

□
□

□ AIDS/CD4 count < 200

Chronic pulmonary disease

□ Primary immunodeficiency
□ Transplant, hematopoietic stem cell
□ Transplant, solid organ

&+521,&0(7$%2/,&',6($6(

□ Diabetes mellitus
□ With chronic complications

/,9(5',6($6(

□ Chronic liver disease
□ Ascites
□ Cirrhosis
□ Hepatic encephalopathy
□ Variceal bleeding
□ Hepatitis C
□ Treated, in SVR
□ Current, chronic

&$5',29$6&8/$5',6($6(

□
□
□
□
□

CVA/Stroke/TIA
Congenital heart disease
Congestive heart failure
Myocardial infarction
Peripheral vascular disease (PVD)

*$6752,17(67,1$/',6($6(

□
□
□
□

□
□
□

19. SUBSTANCE86(

□
□
□
□
□
□
□
□

□
□
□

Malignancy, hematologic
Malignancy, solid organ (non-metastatic)
Malignancy, solid organ (metastatic)

ALCOHOL
ABUSE:

□ Unknown

□ Tobacco
□ E-nicotine delivery system
□ Marijuana

□ Yes
□ No
□ Unknown

□

□

□
□
□
□
□
□
□
□

DURING THE CURRENT HOSPITALIZATION, DID THE PATIENT RECEIVE
MEDICATION ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER?

□ Yes □ No
□ Yes □ No □ Unknown

IF YES, DATE OF DISCHARGE CLOSEST TO DISC :___ ___ - ___ ___ - ___ ___ ___ ___
OR,

DATE UNKNOWN

□

Facility ID: __________

29(51,*+767$<,1/7&),17+(<($5%()25(',6&:
Facility ID: __________

29(51,*+767$<,1/7$&+,17+(<($5%()25(',6&:

□ Yes □ No □ Unknown
□ Yes □ No □ Unknown

Facility ID: __________

685*(5<,17+(<($5%()25(',6&:

□ Yes □ No □ Unknown

&855(17&+521,&',$/<6,6

□ Yes □ No □ Unknown

IF YES, TYPE: □ Hemodialysis

□ Peritoneal □ Unknown

□ Unknown

_____kg

Version Date: 08/2020

1E+(,*+7

_________ft. _______ in. OR
_____cm 

□ Unknown

□ IDU
□ IDU
□ IDU
□ IDU
□ IDU
□ IDU
□ IDU
□ IDU

□ Skin popping
□ Skin popping
□ Skin popping
□ Skin popping
□ Skin popping
□ Skin popping
□ Skin popping
□ Skin popping

□ Non-IDU
□ Non-IDU
□ Non-IDU
□ Non-IDU
□ Non-IDU
□ Non-IDU
□ Non-IDU
□ Non-IDU

□ Unknown
□ Unknown
□ Unknown
□ Unknown
□ Unknown
□ Unknown
□ Unknown
□ Unknown

□ Yes □ No □ N/A (patient not hospitalized or did not have DUD)

'$<6%()25(',6&

□ Yes □ No □ Unknown

Check here if central line in place for > 2 calendar days:Ƒ

85,1$5<&$7+(7(5,13/$&(217+(',6&8372
7+(7,0(2)&2//(&7,2125$7$1<7,0(,17+(

□ Yes □ No □ Unknown
IF YES, CHECK ALL THAT APPLY:
□ Indwelling Urethral Catheter □ Suprapubic Catheter

&$/(1'$5'$<6%()25(',6&

□ Condom Catheter

□ Other (specify):__________

$1<27+(5,1':(//,1*'(9,&(,13/$&(217+(',6&83
727+(7,0(2)&2//(&7,2125$7$1<7,0(,17+(
&$/(1'$5'$<6%()25(',6& □ Yes □ No □ Unknown

IF YES, CHECK ALL THAT APPLY:

□ ET/NT Tube □ Gastrostomy Tube
□ Tracheostomy □ Nephrostomy Tube
PATIENT TRAVELED INTERNATIONALLY
IN THE YEAR BEFORE DISC:

□ AV fistula/graft □ Hemodialysis central line □ Unknown
_________lbs. ______ oz. OR

02'(2)'(/,9(5<&KHFNDOOWKDWDSSO\

□ NG Tube
□ Other (specify):
_____________

IF HEMODIALYSIS, TYPE OF VASCULAR ACCESS:

1D:(,*+7

DUD or abuse
DUD or abuse
DUD or abuse
DUD or abuse
DUD or abuse
DUD or abuse
DUD or abuse
DUD or abuse

□
□

Urinary tract problems/
abnormalities
Premature birth
Spina bifida

&(175$//,1(,13/$&(217+(',6&83727+(7,0(2)
&2//(&7,2125$7$1<7,0(,17+(&$/(1'$5

20. 5,6.)$&7256&KHFNDOOWKDWDSSO\

35(9,286+263,7$/,=$7,21,17+(<($5%()25(',6&:

Connective tissue disease
Obesity or morbid obesity
Pregnant

MuGSI CONDITIONS

Chronic kidney disease
Lowest serum creatinine: ________mg/DL
□ Unknown or not done

□ None □ Unknown

Burn
Decubitus/pressure ulcer
Surgical wound
Other chronic ulcer or chronic
wound
Other (specify):___________

□
□
□

RENAL DISEASE

Marijuana, cannabinoid (other than smoking)
Opioid, DEA schedule I (e.g., heroin)
Opioid, DEA schedule II-IV (e.g., methadone, oxycodone)
Opioid, NOS
Cocaine
Methamphetamine
Other (specify): _____________
Unknown substance

:$6,1&,'(1763(&,0(1&2//(&7('25025(&$/(1'$5
'$<6$)7(5+263,7$/$'0,66,21"

□

Hemiplegia
Paraplegia
Quadriplegia

□ Unknown
'2&80(17('86( ',625'(5'8')$%86(

□
□
□
□
□
□
□
□

□
□
□
□

27+(5

OTHER SUBSTANCES: (Check all that apply)□ None

SMOKING:

6.,1&21',7,21

Cerebral palsy
Chronic cognitive deficit
Dementia
Epilepsy/seizure/seizure disorder
Multiple sclerosis
Neuropathy
Parkinson’s disease
Other (specify): ________________

3/(*,$63$5$/<6,6

0$/,*1$1&<

Diverticular disease
Inflammatory bowel disease
Peptic ulcer disease
Short gut syndrome

&KHFNDOOWKDW
DSSO\ □ None

1(852/2*,&&21',7,21

□ HIV infection

Cystic fibrosis

1F%0,
BBBBBBBBB

□ Unknown

□ Yes □ No □ Unknown

COUNTRY: ____________, ____________, ____________

PATIENT HOSPITALIZED WHILE VISITING
COUNTRY(IES) ABOVE:

□ Yes □ No □ Unknown
PAGE 2 OF 4

Form Approved
Form
Approved
OMB No.
0920-0978
OMBXX-XX-XXXX
No. 0920-0978
Exp. Date:

85,1(&8/785(621/<
. 6,*16$1'6<037206$662&,$7(':,7+85,1(&8/785(

85,1(&8/785(6
21/<25(&25'7+(
&2/21<&2817
________________

Please indicate if any of the following symptoms were reported during the 5 day time period including the
2 calendar days before through the 2 calendar days after the DISC.
Symptoms for patients
≤ 1 year of age only:
□ 8QNQRZQ
□ 1RQH

□ Costovertebral angle pain or tenderness
□ Dysuria
□ Fever [temperature ≥ 100.4 °F (38 °C)]

□ Frequency
□ Suprapubic tenderness
□ Urgency

□ Apnea
□ Bradycardia
□ Lethargy
□ Vomiting

□ Yes □

4D,6$17,0,&52%,$/86(,92525$/,17+('$<6%()25(7+(',6&'2&80(17('"

No

□ Unknown

4E,)<(6&+(&.$//$17,0,&52%,$/686(',17+('$<6%()25(7+(',6&&KHFNDOOWKDWDSSO\□ Unknown

□ Amikacin
□ Amoxicillin
□ Amoxicillin/clavulanic acid
□ Ampicillin
□ Ampicillin/sulbactam
□ Azithromycin
□ Aztreonam
□ Cefazolin
□ Cefdinir
□ Cefepime
□ Cefiderocol
□ Cefixime
□ Cefotaxime
□ Cefoxitin
□ Cefpodoxime
□ Ceftaroline

□ Ceftazidime
□ Ceftazidime/avibactam
□ Ceftizoxime
□ Ceftolozane/tazobactam
□ Ceftriaxone
□ Cefuroxime
□ Cephalexin
□ Ciprofloxacin
□ Clarithromycin
□ Clindamycin
□ Dalbavancin
□ Daptomycin
□ Delafloxacin
□ Doripenem
□ Doxycycline
□ Ertapenem

□ Eravacycline
□ Fidaxomicin
□ Fosfomycin
□ Gentamicin
□ Imipenem/cilastatin
□ Levofloxacin
□ Linezolid
□ Meropenem
□ Meropenem/vaborbactam
□ Metronidazole
□ Moxifloxacin
□ Nitrofurantoin
□ Omadacycline
□ Oritavancin
□ Penicillin
□ Piperacillin/tazobactam

□ Polymyxin B
□ Polymyxin E (colistin)
□ Rifaximin
□ Tedizolid
□ Telavancin
□ Tigecycline
□ Tobramycin
□ Trimethoprim
□ Trimethoprim/sulfamethoxazole
□ Vancomycin
□ IV
□ PO
□ Other (specify): _____________________
□ Other (specify): _____________________

REMINDER: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.
5a DID7+(3$7,(17HAVE A
POSITIVE TEST(S) FOR6$56&R9
02/(&8/$5$66$<6(52/2*<25
27+(5&21),50$725<7(672125
%()25(7+(',6&"

Yes
No
Unknown

5F&29,'1(7&$6(,'

5b. IF YES, COMPLETE TABLE BELOW:

Specimen collection date
FIRST positive test for
SARS-CoV-2 on or before the
DISC:
MOST RECENT positive
test for SARS-CoV-2 on
or before the DISC:

Test type

/
Unknown

/

□
□
□
□
□

/
Unknown

/

□
□
□
□
□

5G11'66,'V3/($6(
3529,'($7/($6721(2)7+(
)2//2:,1*:+(1$33/,&$%/(

Molecular assay
Antigen
Serology
Unknown
Other (specify): ____________
Molecular assay
Antigen
Serology
Unknown
Other (specify): ____________

/RFDOcDVH,'
/RFDOrHFRUG,'
6WDWHFDVHLGHQWLILHU
/HJDF\FDVHLGHQWLILHU
CDC 2019-nCOV ID:

6D:$67+(
,1&,'(17
63(&,0(1
32/<0,&52%,$/"

□ Yes
Yes
□ No
□ Unknown
Unknown

Version Date: 08/2020

6E:+$76&5((1,1*&21),50$725<
0(7+2':$686(')25(6%/
IDENTIFICATION"
(Check all that apply):
None
Unknown

6F ,) 6&5((1,1* &21),50$725<
0(7+2':$686(':+$7:$67+(
5(68/7"

□ Broth Microdilution (ATI detection)
□ ESBL well
□ Expert rule (ATI flag)
□ Unknown
□ Broth Microdilution (Manual)
□ Disk Diffusion
□ E-test
□ Molecular test (specify):_____________
□ Other non-molecular test (specify):_______

□ Positive
Positive
□ Positive
Positive
□ Positive
Positive
□ Positive
Positive
□ Positive
Positive
□ Positive
Positive
□ Positive
Positive
Positive
□ Positive

□

□

□ Negative
Negative
□ Negative
Negative
□ Negative
Negative
□ Negative
Negative
□ Negative
Negative
□ Negative
Negative
□ Negative
Negative
□ Negative
Negative

□ Indeterminate
Indeterminate
□ Indeterminate
Indeterminate
□ Indeterminate
Indeterminate
□ Indeterminate
Indeterminate
□ Indeterminate
Indeterminate
□ Indeterminate
Indeterminate
□ Indeterminate
Indeterminate
Indeterminate
□ Indeterminate

□ Unknown
Unknown
□ Unknown
Unknown
□ Unknown
Unknown
□ Unknown
Unknown
□ Unknown
Unknown
□ Unknown
Unknown
□ Unknown
Unknown
□ Unknown

PAGE 3 OF 4

Form Approved
OMB No.
0920-0978
Form
Approved
OMB No. 0920-0978
Exp. Date: XX-XX-XXXX

2686&(37,%,/,7<5(68/76

Please complete the table below based on the information found in the indicated data source. Shaded antibiotics are required to have the MIC entered into the MuGSI-CM system, if available

'DWD6RXUFH
$QWLELRWLF

Medical Record
ecord
0,&
,QWHUS

Microscan
0,&

Vitek

,QWHUS

Phoenix

0,& ,QWHUS 0,& ,QWHUS

Sensititre
MIC

Interp

Kirby-Bauer

E-test

Zone Diam Interp MIC

Interp

$PLNDFLQ
$PR[LFLOOLQ&ODYXODQDWH
$PSLFLOOLQ
$PSLFLOOLQ6XOEDFWDP
$]WUHRQDP
&HID]ROLQ
&()(3,0(
&HILGHURFRO
&()27$;,0(
&HIR[LWLQ
&()7$=,',0(
&HIWD]LGLPH$YLEDFWDP
&HIWROR]DQH7D]REDFWDP
&()75,$;21(
&HSKDORWKLQ
&LSURIOR[DFLQ
&2/,67,1
'25,3(1(0
'R[\F\FOLQH
(UDYDF\FOLQH
(57$3(1(0
)RVIRP\FLQ
*HQWDPLFLQ
,0,3(1(0
,PLSHQHPUHOHEDFWDP
/HYRIOR[DFLQ
0(523(1(0
0HURSHQHPYDERUEDFWDP
0LQRF\FOLQH
1LWURIXUDQWRLQ
2PDGDF\FOLQH
3LSHUDFLOOLQ7D]REDFWDP
3OD]RPLFLQ
32/<0<;,1%
5LIDPSLQ
7HWUDF\FOLQH
7,*(&<&/,1(

27D :$6&$6(),567,'(17,),('7+528*+$8',7"

7REUDP\FLQ
□ Yes
Trimethoprim-sulfamethoxazole
□ No

28a. WAS
CASE FIRST IDENTIFIED THROUGH AUDIT?
27G
&200(176

Yes
No
28e. COMMENTS:

CS295460-B

27F62,1,7,$/6

27E&5)67$786

□ Complete
□ Pending
□ Chart unavailable after 3 requests

28b. CRF STATUS:

Complete
Pending
Chart unavailable after 3 requests

28c. SO INITIALS:

28d. DATE OF ABSTRACTION:
___ ___ - ___ ___ - ___ ___ ___ ___

PAGE 4 OF 4